Comorbidities in COPD Just as Important to Treat as Disease Itself

Photo Credit: Magicmine

COPD often coexists with other chronic conditions, which worsen the prognosis, exacerbate symptoms, and reduce the quality of life.

Chronic obstructive pulmonary disease (COPD) often coexists with other chronic conditions, which worsen the prognosis, exacerbate symptoms, and reduce QOL for patients with COPD, according to research published online in BMC Pulmonary Medicine.

“COPD is also characterized by a systemic component, with an increased prevalence of concurrent chronic diseases,” the study authors wrote.

“They are defined as comorbidities when describing the burden of several chronic illnesses coexisting with a particular disease of interest, in this case, COPD. By contrast, when the importance relies in the interaction between multiple chronic conditions in the same subject, multimorbidity seems to be a more appropriate concept since the simultaneous combination of these chronic diseases affects differently the symptoms, prognosis, and treatment of an individual patient.”

The specific impact of these comorbidities on the clinical control of COPD has not been extensively studied. For this observational, multicenter, cross-sectional study, researchers aimed to investigate the relationship between individualized comorbidities and COPD clinical control criteria among 4,801 patients with severe COPD.

The study defined clinical control criteria based on COPD assessment test (CAT) scores and the number of exacerbations in the previous three months. A binary logistic regression adjusted for age and forced expiratory volume in the first second (FEV₁%) identified comorbidities potentially associated with poor COPD clinical control. The secondary endpoints included the relationship between comorbidities, CAT scores, and recent exacerbations.

The most common comorbidities identified were arterial hypertension (51.2%), dyslipidemia (36.0%), diabetes (24.9%), obstructive sleep apnea-hypopnea syndrome (14.9%), anxiety (14.1%), heart failure (11.6%), depression (11.8%), atrial fibrillation (11.5%), peripheral arterial vascular disease (10.4%), and ischemic heart disease (10.1%). After adjusting for age and FEV₁%, the study found that cardiovascular diseases (heart failure, peripheral vascular disease, atrial fibrillation), psychological disorders (anxiety, depression), metabolic diseases (diabetes, arterial hypertension, abdominal obesity), sleep disorders, anemia, and gastroesophageal reflux were significantly associated with poor clinical control of COPD. These comorbidities were also linked to higher CAT scores and more frequent exacerbations.

The findings highlighted the high prevalence of comorbidities in patients with severe COPD and their detrimental impact on clinical control criteria. Comorbidities were shown to affect the health-related quality of life, as measured by CAT scores, and increased the likelihood of recent exacerbations. The study suggests that managing comorbidities is crucial for improving clinical control in COPD patients.

The study’s results align with previous research showing the significant prevalence of comorbidities in COPD patients and their association with worse outcomes. The results emphasize the need for comprehensive evaluation and management of comorbidities in COPD patients to enhance their clinical control and QOL.

This study underscored the importance of addressing comorbidities in the clinical management of COPD. The presence of comorbidities, such as cardiovascular, psychological, metabolic diseases, sleep disorders, anemia, and gastroesophageal reflux, significantly affects COPD clinical control. Therefore, according to the experts, integrating the treatment of these conditions into the overall management plan for COPD patients could potentially improve their prognosis, reduce exacerbations, and enhance their quality of life. Further research is needed to explore the impact of treating these comorbidities on COPD clinical control and patient outcomes.

“Our data confirm the relevance of several comorbidities in COPD clinical control criteria, supporting the notion that these conditions should be carefully evaluated in future studies,” the authors concluded.